Company Overview and News
TORONTO, ON / ACCESSWIRE / April 23, 2018 / MPX Bioceutical Corporation ("MPX" or the "Company") (CSE: MPX; OTCQB: MPXEF) announces that it will be participating in a panel discussion on ''What's Next for Cannabis Investors,'' on Tuesday, April 24, 2018, at 1:10 pm (PST) at the Planet MicroCap Showcase in Las Vegas, NV. The Company will also be presenting a corporate update at 9:00 am (PST) on Wednesday, April 25, 2018, in addition to conducting one-on-one meetings the morning of April 26, 2018.
TORONTO, April 09, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“MPX” or the “Company”) (CSE:MPX) (OTC:MPXEF) is pleased to announce that the official opening of the its newest “Health for Life” medical marijuana dispensary in the Metropolitan Phoenix area, located at the junction of E. Main and Crimson in the suburb of Apache Junction. This brings the number of dispensaries under MPX management in Arizona’s Sun Valley to four.
TORONTO, April 03, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“MPX” or the “Company”) (CSE:MPX) (OTC:MPXEF) has reported that its managed Arizona assets have recorded their best revenue month in March with sales of cannabis and cannabis concentrates hitting the US$4.0 (CDN$5.2) million mark for the first time.
TORONTO, ONTARIO--(Marketwired - Nov. 3, 2017) - The Canadian Bioceutical Corporation has announced a name change to MPX Bioceutical Corporation. Shares will begin trading under the new name and symbol on November 6, 2017.
A participant practices rolling a joint at the Cannabis Carnivalus 4/20 event in Seattle, April 20, 2014. — Reuters picNEW YORK, July 28 — Canada’s stock market has been ablaze with reefer madness, but the country’s largest exchange is grappling with how to deal with pot companies that have investments in the US, where marijuana is still banned by federal law.
TORONTO, ONTARIO--(Marketwired - April 18, 2017) - The Canadian Securities Exchange (CSE or the Exchange) announced results for the first quarter of 2017 today showing exceptional year-on-year growth in share turnover, value traded and the total value of financings completed by CSE listed companies. The exchange also welcomed 12 new listed companies during the quarter and co-hosted events across Canada, noting a significant increase in investor interest as the operating environment for North American small-cap companies continued to strengthen.
TORONTO, ON / ACCESSWIRE / April 4, 2017 / The Canadian Bioceutical Corporation (the "Company" or "BCC") (CSE: BCC, OTC PINK: CBICF) today announces that the Company's press release announcing the Massachusetts acquisition, issued this morning, contains an error in that the sub-heading states the call is on April 4th. The correct date for the call is April 5th. The Company apologizes for the confusion and looks forward to speaking with investors on the call.
TORONTO, ON / ACCESSWIRE / April 3, 2017 / The Canadian Bioceutical Corporation (the "Company" or "BCC") (CSE: BCC, OTC PINK: CBICF) is pleased to announced that the Company has retained Echelon Wealth Partners Inc. ("Echelon") to assist BCC with assessing, structuring and negotiating mergers and acquisitions, and general corporate and financial advisory services, as well as introduce the Company to prospective investors.
TORONTO, ON / ACCESSWIRE / March 30, 2017 / The Canadian Bioceutical Corporation (the "Company" or "BCC") (CSE: BCC, OTC: CBICF) today announced that it intends to raise up to US$20,000,000 in a private placement by issuing approximately 54,000,000 common shares in the capital of the Company at a price of CAD$0.50 per common share. The Company will determine the number of Common Shares issuable pursuant to the offering by deeming the United States dollar / Canadian dollar currency conversion rate applicable for the issuance of common shares prior to closing.
TORONTO, ON / ACCESSWIRE / March 20, 2017 / The Canadian Bioceutical Corporation (the "Company" or "BCC") (CSE: BCC, OTC PINK: CBICF) is pleased to announced that effective March 17, 2017 at close of trading, the Company has been added to the CSE Composite Index. The index is comprised of shares of listed companies that meet market capitalisation, trading and seasoning criteria established by the exchange.
11h - Asif
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
11h - Asif
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
2018-04-23 - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...
as of ET